EpiAxis Therapeutics is among the emerging-growth entrepreneurial companies that will present at youngStartup Ventures Network’s Venture Summit West 2022, which is being held in Silicon Valley from 19-20 July 2022.

The exclusive venture summit is dedicated to showcasing early-stage venture capitalists, corporate venture capitalists and angel investors committed to funding venture backed, emerging and early stage companies as well as showcasing more than 100 top innovators in the tech, fintech, cleantech, lifesciences, healthcare and medtech sectors.

More than 1000 attendees are expected at the summit, which will feature insightful discussions, the newest technologies and latest trends currently shaping the future.

EpiAxis recently published the results of its pioneering clinical trial EPI-PRIMED in leading cancer journal Frontiers of Oncology. EPI-PRIMED is the first time that an epigenetic inhibitor has been used in combination with chemotherapy to treat metastatic cancer. The findings of the EPI-PRIMED study give EpiAxis a solid foundation for its next clinical trial using its novel peptide inhibitors. The company is currently working with The Sage Group to raise US$12million to advance a candidate into an IND enabled program.

Dr Chrisp will pitch at Venture Summit West 2022 during Round III – Life Sciences/Healthcare at 1:50 pm (PDT) on 20 July 2022.

For more information about EpiAxis Therapeutics and partnering opportunities for its pipeline drug candidates, please contact:

Dr Jeremy Chrisp
Phone: +61 421 012 268
j.chrisp@epiaxistherapeutics.com

Dr Bill Mason
The Sage Group
Tel: +44 (0) 7785 950134
wtm@sagehealthcare.com